Drugs, devices and delivery considerations in parenteral pharmaceutical care, or, what are they doing with our drugs?
Allen, L.V.
PDA Journal of Pharmaceutical Science and Technology 49(6): 306-308
1995
ISSN/ISBN: 1079-7440 PMID: 8581464 Document Number: 440333
Document emailed within 1 workday
Related Documents
Wrześniok, D.; Buszman, E.; Matusiński, B. 2003: Drugs ototoxicity. Part II. Loop diuretics, nonsteroidal anti-inflammatory drugs, antineoplastic and antimalarial drugs Wiadomosci Lekarskie 56(7-8): 369-374McGettigan, P.; Roderick, P.; Mahajan, R.; Kadam, A.; Pollock, A.M. 2015: Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs PLOS Medicine 12(5): E1001826; Discussion E1001826
Shepherd, M. 2011: Administration of drugs 3: parenteral Nursing Times 107(36): 16
Nakamura, H. 2000: Pharmaceutical point of views on "Drugs and pharmacology" Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 116(1): 54
Sánchez, B.; Rivas, P.; Mario Alvarez, M.; Raimundo García, J. 1989: Tetanus in addicts on parenteral drugs Anales de Medicina Interna 6(8): 448
Rabe, T.; Runnebaum, B. 1987: Parenteral contraceptive drugs: depot progestins Wiener Medizinische Wochenschrift 137(20-21): 474-479
Masters, D.B. 2002: Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices Official Gazette of the United States Patent and Trademark Office Patents 1254(5)
Carrillo Norte, J.A.; Postigo Mota, S. 2012: Generic drugs: we must cut pharmaceutical spending but undertaking drug quality Revista de Enfermeria 35(2): 10-19
Tse, F.L.; Welling, P.G. 1980: Bioavailability of parenteral drugs I. Intravenous and intramuscular doses Journal of the Parenteral Drug Association 34(5): 409-421
Ogawa, Y. 1994: Application of a bacterial endotoxin test for parenteral drugs Eisei Shikenjo Hokoku. Bulletin of National Institute of Hygienic Sciences 112: 209-211
Moldenhauer, H. 1979: Pharmaceutical technology problems in the preparation of drugs for the treatment of cardiovascular diseases Die Pharmazie 34(8): 500-506
Koba, M.; Koba, K.; Przyborowski, L. 2008: Application of UV-derivative spectrophotometry for determination of some bisphosphonates drugs in pharmaceutical formulations Acta Poloniae Pharmaceutica 65(3): 289-294
Ammar, H.O.; el-Nahhas, S.A. 1995: Improvement of some pharmaceutical properties of drugs by cyclodextrin complexation. 3. Bromhexine hydrochloride Die Pharmazie 50(6): 408-410
Zierenberg, O. 1997: Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry Zeitschrift für Arztliche Fortbildung und Qualitatssicherung 91(7): 596-600
Nuhn, P.; Köhler, T. 1991: The biochemical basis of pharmaceutical chemistry. 10. Enzymes and enzyme inhibitors as drugs Die Pharmazie 46(5): 365-382
Guilfoyle, D.E.; Yager, J.F. 1984: Procedures used for sterility testing of parenteral drugs by an FDA field laboratory Journal of Parenteral Science and Technology: a Publication of the Parenteral Drug Association 38(4): 138-141
Casola, A.R. 1975: I. Federal regulations concerning use of asbestos filters in manufacturing parenteral drugs Bulletin of the Parenteral Drug Association 29(5): 216-218
Tetzlaff, R.F. 1983: Systems validation for parenteral clinical drugs--application to R&D and QC laboratories Journal of Parenteral Science and Technology: a Publication of the Parenteral Drug Association 37(2): 45-50
Sánchez Fuentes, D.; Barragán Casas, J.M.; Garcinuño Jiménez, M.A.; Martín Casado, M.; Martín Marcos, M. 1994: Decision regarding chemoprophylaxis with isoniazid in patients using parenteral drugs and infected with HIV Revista Clinica Espanola 194(2): 81-86
Whitney, H.A.; Covington, T.R. 1971: The future impact of clinical pharmacy on parenteral drugs and the industry Bulletin of the Parenteral Drug Association 25(2): 87-97